Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29473405 | 0.88 | POLB (0.52) | CYP1A2CYP2C19POLBGAA | |
| SCHEMBL19220498 | 0.88 | MAPK1 (0.41) | CYP1A2CYP2C19ALDH1A1POLBMAPT | |
| SCHEMBL17187688 | 0.88 | POLB (0.52) | CYP1A2CYP2C19POLBGAA | |
| SCHEMBL17199107 | 0.87 | HDAC3 (0.48) | ALDH1A1GAA | |
| SCHEMBL17199290 | 0.84 | HTT (0.43) | CYP1A2CYP2C19ALDH1A1POLBMAPT | |
| Trifluoroacetic Acid SCHEMBL17187687 | 0.83 | POLB (0.45) | CYP1A2CYP2C19ALDH1A1POLBMAPT | |
| SCHEMBL17199096 | 0.82 | CYP1A2 (0.63) | CYP1A2CYP2C19ALDH1A1POLBPTPRC | |
| SCHEMBL12377714 | 0.82 | MEN1 (0.43) | CYP1A2CYP2C19ALDH1A1POLBMAPT | |
| SCHEMBL12415465 | 0.80 | KDM4E (0.45) | ALDH1A1POLBMAPT | |
| Trifluoroacetic Acid SCHEMBL22203993 | 0.79 | HTT (0.38) | CYP1A2CYP2C19ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988358-B2 | Phenazinium mediators | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226068-A1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-10 | — | — | US | disclosed |
| WO-2015158645-A1 | PHENAZINIUM MEDIATORS | ROCHE DIAGNOSTICS GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226068-A1 | PHENAZINIUM MEDIATORS | IL5, TRPV5, TRPM5 | CYP1A2 722/4885CYP2C19 2552/4885ALDH1A1 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.